Related Experiment Video

Updated: Nov 8, 2025

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization
06:01

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Published on: June 7, 2016

6.9K

Hindering the Synchronization Between miR-486-5p and H19 lncRNA by Hesperetin Halts Breast Cancer Aggressiveness

Ramah M Abdallah1, Aisha M Elkhouly1, Raghda A Soliman1

  • 1Pharmaceutical Biology Department, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo, Egypt.

Anti-Cancer Agents in Medicinal Chemistry
|April 22, 2021
PubMed
Abstract

Insights

Hesperitin modulates the miR-486-5p/H19/ICAM-1 axis, impacting metastatic breast cancer (mBC) cell aggressiveness. This natural compound offers a potential therapeutic strategy by targeting key regulatory ncRNAs and ICAM-1 in mBC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Crosstalk between non-coding RNAs (ncRNAs) is emerging in metastatic breast cancer (mBC), yet remains understudied.
  • The roles of H19 and miR-486-5p in mBC are debated, and ICAM-1 is a known driver of metastasis.
  • Natural compounds' ability to modulate ncRNA circuits is recognized, but hesperitin's effect on mBC-related ncRNAs is unexplored.

Purpose of the Study:

  • To investigate the impact of hesperitin on the miR-486-5p/H19/ICAM-1 axis in metastatic breast cancer.
  • To explore the therapeutic potential of hesperitin in modulating ncRNA interactions and metastatic progression.

Main Methods:

  • Bioinformatic analysis and cell culture (MDA-MB-231, MCF-7) with oligonucleotide transfection or hesperitin treatment.
  • Gene expression analysis via q-RT-PCR, protein assessment using ELISA, and cytotoxicity evaluation (LDH assay).
  • Functional assays including MTT, colony formation, and migration assays to assess mBC cell behavior.

Main Results:

  • Paradoxical expression of miR-486-5p and H19 observed in breast cancer patients.
  • miR-486-5p mimics and H19 siRNAs suppressed ICAM-1 and mBC hallmarks, revealing a novel bi-directional crosstalk.
  • Hesperitin restored miR-486-5p, inhibited H19 lncRNA and ICAM-1, and reduced mBC cell aggressiveness.

Conclusions:

  • The miR-486-5p/H19/ICAM-1 axis represents a critical regulatory pathway in mBC.
  • Hesperitin effectively modulates this axis, targeting interconnected upstream regulators (miR-486-5p and H19) and downstream effectors (ICAM-1).
  • Hesperitin demonstrates selective regression of mBC cell aggressiveness, highlighting its therapeutic potential.
Keywords:
H19ICAM-1breast cancerhesperitinmetastasismiR-486-5p

More Related Videos

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.9K
Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

17.8K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.3K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
22.8K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.3K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.1K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K